- SEK 02.06.2026 17:51:27
| Leverage Risk | Yes |
| Market Risk | Yes |
| Counterparty Risk | Yes |
| Currency Risk | Yes * |
*No currency risk exists if the product in question is based on your domicile currency.
The financial instruments are associated with risks and therefore you should not buy the financial instruments described on this website unless you are prepared to sustain a total loss of the investment plus any commission or other transaction charges that may be incurred. The financial instruments described on this website are complex securities and may be difficult to understand. You should not buy these securities unless you are a sophisticated investor who understands and has previous experience in investing in such products. Potential investors should read the prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the securities. The approval of the prospectus by the relevant competent authority should not be understood as an endorsement of the securities.
During periods where the Relevant Underlying is closed any secondary market price may be estimated using an alternative reference asset.
| Financing Level | 227.9426 DKK |
| Reset Level | 243.90 DKK |
| Daily Leverage | 5 |
| Ratio | 266,879.074218 |
| Multiplier | 0.000004 |
| Name | BULL NOVO X5 AVA 4 |
| Short Code | BULL NOVO X5 AVA 4 |
| ISIN | GB00BNTQ7G43 |
| Issuer | MORGAN STANLEY & CO. INTERNATIONAL |
| Currency | SEK |
| Product Type | Bull & Bear |
| Underlying | Novo Nordisk B |
| Underlying Currency | DKK |
| Financing Spread p.a. | 1.50 % |
| First Day Of Trading | 03.09.2021 |
| Daily Change (Bid) | - |
| - | |
| Issuer Call Date | 01.06.2026 |
| Last Update | 02.06.2026 17:51:27 |
| Day High | - |
| Day Low | - |
| Leverage Risk | Yes |
| Market Risk | Yes |
| Counterparty Risk | Yes |
| Currency Risk | Yes * |
*No currency risk exists if the product in question is based on your domicile currency.
The financial instruments are associated with risks and therefore you should not buy the financial instruments described on this website unless you are prepared to sustain a total loss of the investment plus any commission or other transaction charges that may be incurred. The financial instruments described on this website are complex securities and may be difficult to understand. You should not buy these securities unless you are a sophisticated investor who understands and has previous experience in investing in such products. Potential investors should read the prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the securities. The approval of the prospectus by the relevant competent authority should not be understood as an endorsement of the securities.
During periods where the Relevant Underlying is closed any secondary market price may be estimated using an alternative reference asset.
| Date | Events | Adjustments | Value Before Event | Value After Event |
|---|---|---|---|---|
| 27/03/2026 | Cash Dividend |
|
|
|
| 15/08/2025 | Cash Dividend |
|
|
|
| 28/03/2025 | Cash Dividend |
|
|
|
Thank you for your time and interest in Exchange Traded Products
For enquiries or complaints regarding Exchange Traded Products, please use contact details below:
Phone: +46 (0) 8-409 423 23
Email: avanzamarkets@avanza.se
For general enquiries regarding Exchange Traded Products, please use contact details below:
Email: etpsweden@morganstanley.com
